Dr Susan Mary Hyde, MD | |
1355 N 205th St, Shoreline, WA 98133-3215 | |
(206) 542-5656 | |
Not Available |
Full Name | Dr Susan Mary Hyde |
---|---|
Gender | Female |
Speciality | Pediatrics |
Location | 1355 N 205th St, Shoreline, Washington |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1306929294 | NPI | - | NPPES |
8234437 | Medicaid | WA |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208000000X | Pediatrics | MD00024455 (Washington) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Susan Mary Hyde, MD Po Box 50095, Seattle, WA 98145-5095 Ph: (206) 543-6420 | Dr Susan Mary Hyde, MD 1355 N 205th St, Shoreline, WA 98133-3215 Ph: (206) 542-5656 |
News Archive
A new study finds many phase I trials for new cancer fighting drugs never get reported in peer-reviewed journals, and says investigators should be committed not just to finding novel compounds, but also to make sure final results of their studies be disseminated to the medical community.
Scientists from MitoChroma Research have recently announced a patent-pending discovery that could complement current medical management modalities for Type 2 Diabetes, insulin resistance and the set of related conditions called "Metabolic Syndrome."
Advanced Cell Technology, Inc., a leader in the field of regenerative medicine, announced today that China's State Intellectual Property Office (SIPO) has allowed the Company's patent application to provide broad intellectual property protection in China for the manufacturing and pharmaceutical preparations of retinal pigment epithelial (RPE) cells from human embryonic stem cells (hESCs).
The cover for issue 2 of Oncotarget features Figure 4, "Combination therapy TA99/ICB reduced the lung tumor burden in the B16 model of metastases," published in "Improved therapeutic efficacy of unmodified anti-tumor antibodies by immune checkpoint blockade and kinase targeted therapy in mouse models of melanoma" by PĂ©rez-Lorenzo, et al. which reported that here, the authors showed that removing immune suppression and enhancing stimulatory signals increased the anti-tumor activity of unmodified TA99 antibodies with a significant reduction of growth of solid tumors and lung metastases in mouse models of melanoma.
› Verified 8 days ago
Ellen Simone Passloff, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 1201 N 175th St, Shoreline, WA 98133 Phone: 206-401-3200 | |
Anne H Reese, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 357 Nw Richmond Beach Rd, Richmond Pediatrics, Shoreline, WA 98177 Phone: 206-546-2421 Fax: 206-546-8436 | |
Dr. Marion L Folkemer, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 1355 N 205th St, Shoreline, WA 98133 Phone: 206-542-5656 Fax: 206-520-1899 | |
Melissa Cecilia Walsh, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 357 Nw Richmond Beach Rd, Shoreline, WA 98177 Phone: 206-546-2421 | |
Mr. Donald Robert Milligan, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 15230 15th Ave Ne, Shoreline, WA 98155 Phone: 206-361-3087 Fax: 206-361-3035 | |
Mrs. Melissa Nicole Genualdi, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 604 Nw Richmond Beach Rd, Shoreline, WA 98177 Phone: 206-533-2900 |